Known Unknowns: Challenges and Opportunities for FGFR2 Fusion Detection in Solid Tumors
Date: Tuesday, February 4 – 12:00 – 1:30 pm EST
Speakers:
Leonard Angka PhD
Canadian Cholangiocarcinoma Collaborative (C3),
Ottawa
Pinaki Bose PhD
OncoHelix Inc.
University of Calgary, Calgary
Tracy Stockley PhD, FCCMG, FACMG
Scheme Director, Canadian Biomarker Quality Assurance
Professor, Department of Laboratory Medicine & Pathobiology
University Health Network, Toronto
Stockley is a molecular geneticist and Director of Hereditary Genomics in the Genome Diagnostics Division at University Health Network in Toronto. At UHN, Dr. Stockley participates in overseeing genetic testing for oncology, including hereditary cancer, companion diagnostics and the development of genomic tests for emerging biomarkers. Dr. Stockley has research and clinical interests in improving quality assurance in high-complexity laboratory testing, and engages in quality activities with multiple national and international organizations, including Health Canada, the Canadian Biomarker Quality Assurance program, the College of American Pathologists, Association for Molecular Pathology, the European Molecular Quality Network and the International Organization for Standardization (ISO). In addition, Dr. Stockley is a Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto, and is a past President of the Canadian College of Medical Geneticists (CCMG). Dr. Stockley is also a cancer survivor with a personal interest in patient support and engagement in research.
Learning Objectives:
- Describe the NGS methods used for detection of FGFR2 gene fusions in Canadian clinical laboratories in the FGFR2 CBQA scheme, and the implications for detection of rare and common gene fusions
- Recognize the importance of NGS test methods for the detection of FGFR2 gene fusions in a cohort of Canadian patients
- Review the mission and ongoing activities of the Canadian Cholangiocarcinoma Collaborative (C3)